Abstract Titles

Skip to Late-Breaking Abstracts »

All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).

Abstract Titles

Onsite Posters

Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.

ePosters

ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.


Search word or phrase:

# Type Title Authors Category Keywords
1 Poster Presentation Dissecting β-catenin associated inflammation in patients with desmoid fibromatosis to identify prognostic biomarkers Laura Bergamaschi; Federica Perrone; Francesca Rini; Licia Rivoltini; Chiara Castelli, PhD; Alessandro Gronchi; Chiara Colombo; Viviana Vallacchi Biomarkers, Immune Monitoring, and Novel Technologies Immune monitoring;Inflammation
2 Poster Presentation Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) Heather Cohen; Carly Campbell; Kristen Hurov; Johanna Lahdenranta; Tara Gelb; David Galbraith; Dan Rozelle; Mate L. Nagy; Qingyan Au; Erinn A. Parnell, PhD; Phil Brandish; Sebastien Hazard; Dominic Smethurst; Nicholas Keen; Stephen J. Blakemore Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Bispecifics;Costimulation;Gene expression;Immune contexture;Immune monitoring;Solid tumors;T cell;Targeted therapy;Tumor microenvironment
3 Poster Presentation Development of an integrated method to quantify receptor occupancy for agonist immunotherapeutics that stimulate target cells to migrate from the peripheral blood Louis E. Gonzalez, PhD; Bo Ma, PhD; Robert Hernandez, PhD; Hannah McKay; Fatima Rangwala, MD, PhD; Lini Pandite, MD; Taylor H. Schreiber, MD, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Immune contexture
4 Poster Presentation 3D Coculture platform reveals insights into patient autologous immune cell-tumor interaction and immune modulation in vitro Garima Kaushik, PhD; Amy K. Wesa, PhD Biomarkers, Immune Monitoring, and Novel Technologies Checkpoint blockade;Cytokine;Immune monitoring;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
5 Poster Presentation CD274 (PD-L1) gene expression and the 27-gene immuno-oncology (IO) assay are associated with efficacy to immune checkpoint inhibitor treated patients with non-small cell lung cancer (NSCLC). Tyler J. Nielsen, MS; Matthew G. Varga, PhD; Kim McGregor, MD; Douglas T. Ross, MD, PhD; Brock L. Schweitzer, PhD; Rob S. Seitz; Gregory Vidal, MD PhD Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Biomarkers;Clinical study;Gene expression;RNA;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
6 Poster Presentation Immune correlates of clinical benefit in patients with HPV-associated malignancies treated with bintrafusp alfa Yo-Ting Tsai, PhD; Renee N. Donahue, PhD; Nicole J. Toney, Ph.D; Julius Strauss, MD; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD Biomarkers, Immune Monitoring, and Novel Technologies Antibody;Biomarkers;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Solid tumors;T cell;Targeted therapy
7 Poster Presentation Analytical comparison of a PD-L1 22C3 antibody laboratory-developed test protocol on the Benchmark XT and PD-L1 IHC 22C3 pharmDx: pan-tumor and triple-negative breast cancer samples Gilad W. Vainer; Ghadeer Zatara; Lingkang Huang, Ph.D.; Shanthy Nuti, PhD; Kenneth Emancipator, MD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Solid tumors
8 Poster Presentation Multiparameter characterization of CAR T cells Xueting Wang, M.Sc.; Christina Pitzka; Daniela Rheindorf; Nadine Mockel-Tenbrinck; Tatjana Holzer, PhD; Anne Richter, PhD; Toni Cathomen, PhD; Cesar Evaristo, PhD Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy;Biomarkers;CAR T cells;Costimulation;COVID and Immunotherapy;Immune monitoring;Immune tolerance;Leukemia/Lymphoma;Tumor evasion;Tumor microenvironment
9 Poster Presentation BRaf mutations are associated with T-helper cell infiltration and polarization in melanoma Michael B. Ware, PhD; Bhavana Pavuluri; Aubrey S. Smith, BS; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Anna C. Cole, BA; Chrystal M. Paulos, PhD Biomarkers, Immune Monitoring, and Novel Technologies Chemokine;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
10 Poster Presentation Tertiary lymphoid structure in pancreatic ductal adenocarcinoma; a potential target in an immunologically inert malignancy Kasimu U. Adoke, MBBS, FMCPath; Sanusi M. Haruna Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy;Antibody;B cell;Biomarkers;Dendritic cell;Immune toxicity;T cell
11 Poster Presentation Molecular characterization of naturally occurring colorectal and breast cancer in non-human primates to model human immunotherapeutic agents Simon Deycmar, PhD; Brendan Johnson, DVM; Declan Ryan; William S. Sills, DVM; David L. Caudell, PhD; Greg Dugan, PhD; Kiran K. Solingapuram Sai, PhD; Michael Hettich, PhD; Bruno Gomes, DVM PhD; Maurizio Ceppi; Mark Cline, DVM PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Bispecifics;Carcinogenesis;Checkpoint blockade;Immune monitoring;Neoantigens;Solid tumors
12 Poster Presentation Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4-1BB agonist Heather Kinkead, PhD; Chelsie Macedo; Angelica Sanabria; Garrett Cyprus; Rajay Pandit; James Kalabus, PhD; Bryan R. Becklund, PhD; Florian J. Sulzmaier, PhD; John C. Timmer, PhD; Quinn Deveraux, PhD; Brendan P. Eckelman, PhD; Analeah B. Heidt, PhD Biomarkers, Immune Monitoring, and Novel Technologies Antibody;Biomarkers;Bispecifics;Costimulation;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
13 Poster Presentation DexterTM microfluidic platform coupling single-cell resolution of dynamic tumor-immune interaction with AI for elucidating mechanistic modulation in cancer immunotherapy Pradip K. Majumder, Ph.D.; Biswanath Majumder; Ranjeet Singh; Abhay Sane; Rushil Manglik; Ravi R. Keshari; Mohanasundaram S. M; Ashwin Dr. Lal, Ph.D. Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;CAR T cells;Cytokine;Dendritic cell;Immune monitoring;Monocyte/Macrophage;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
14 Poster Presentation Claudin-6 affects the cell cycle and p53 signaling in Gastric cancer. Sanyog Dwivedi, Mr., MSC Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Biomarkers;Carcinogenesis;Gene expression;Metabolism;Solid tumors
15 Poster Presentation First-line platinum-based chemotherapy combined with PD-1/PD-L1 inhibitors (ICI) prevents hyperprogression in non-small cell lung cancer (NSCLC) patients by reducing circulating immature neutrophils Roberto Ferrara, MD; Giuseppe Lo Russo; Elena Jachetti; Giuseppina Calareso; Claudia Proto; Arsela Prelaj; Giulia Galli; Diego Signorelli; Marta Brambilla; Alessandro De Toma; Mario Occhipinti; Sara Manglaviti; Giulia Apollonio; Laura Mazzeo; Monica Ganzinelli; Antonia Martinetti; Filippo De Braud; Marina Garassino; Mario Paolo Colombo; Sabina Sangaletti, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Chemotherapy;Granulocyte;Immune monitoring;Myeloid cells;Solid tumors
16 Poster Presentation Tumor growth inhibition mediated by a single dose of intratumoral TransCon™ TLR7/8 agonist was associated with activated circulating T and B cells and sustained low levels of systemic cytokines Amer M. Mirza, PhD; Luis A. Zuniga, PhD; Karan Uppal, PhD; Kathy Bang; Enping Hong, PhD; Simran Sabharwal, PhD; Yuchi Lee, PhD; Salomon Martinez; David Rosen, PhD; Juha Punnonen, MD, PhD Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy;Biomarkers;Chemokine;Cytokine;Dendritic cell;Immune monitoring;Monocyte/Macrophage;Myeloid cells;T cell lineages;TLR
17 Poster Presentation Predictive soluble biomarkers of immune response to checkpoint blockade in Non-Small Cell Lung Cancer (NSCLC) patients Afsheen Raza, PhD; Reyad Mohsen; Aladdin Kanbour; Abdul Rehman Zar Gul; Anite Philip; Suma Vijayakumar; Shereena Hydrose; Maysaloun Merhi; Varghese Inchakalody; Shahab Uddin; Mohammed Ussama Al Homsi; Said Dermime Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Immune monitoring
18 Poster Presentation Systemic immune profiling of advanced biliary tract cancer patients defines altered cytokines and immune cell populations Amanda N. Ruggieri, MS; Mark Yarchoan, MD; Yuan Liu, PhD; Subir Goyal, Ph.D; Elad Sharon, MD, MPH; Helen Chen, MD; Brian M. Olson, PhD; Shishir K. Maithel, MD; Bassel El-Rayes, MD; Nilofer Azad, MD; Gregory B. Lesinski, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Chemokine;Clinical study;Immune monitoring;Myeloid cells;Solid tumors;T cell
19 Poster Presentation Exome-scale liquid biopsy characterization of emerging immune resistance mechanisms in treatment-resistant GIST Charles W. Abbott, PhD; Niamh Coleman; Jing Wang; Josette M. Northcott; Fabio Navarro; Lee D. McDaniel, Jr., MD, MSE; Eric Levy, PhD; Rachel M. Pyke, PhD; Filip Janku, MD, PhD; Richard Chen, MD; Sean M. Boyle, PhD, MS Biomarkers, Immune Monitoring, and Novel Technologies Gene expression;Neoantigens;T cell
20 Poster Presentation Tumor-informed liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy Charles W. Abbott, PhD; Nikita Bedi; Jing Wang; Josette M. Northcott; Rachel M. Pyke, PhD; Robin Li, MS; Lee D. McDaniel, Jr., MD, MSE; Eric Levy, PhD; Mena Mansour; Dimitrios Colevas, MD; John Lyle, PhD; John B. Sunwoo, MD; Sean M. Boyle, PhD, MS; Richard Chen, MD Biomarkers, Immune Monitoring, and Novel Technologies Antigen presenting cells;Biomarkers;Neoantigens;T cell;Tumor evasion
21 Poster Presentation Neutrophil extracellular traps (NETs) can be measured non-invasively with CPa9-HNE - biomarker potential across different solid tumor types in the immuno-oncology setting Christina Jensen, MSc, PhD; Jeppe Thorlacius-Ussing; Joachim H. Mortensen; Morten A. Karsdal; Nicholas Willumsen Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Immune monitoring;Immune suppression;Myeloid cells;Post-translational modifications;Solid tumors;Tumor microenvironment;Tumor stroma
22 Poster Presentation The potential of serum autoantibodies against type III collagen in cancer Christina Jensen, MSc, PhD; Jeppe Thorlacius-Ussing; Patryk Drobinski; Morten A. Karsdal; Anne-Christine Bay-Jensen; Nicholas Willumsen Biomarkers, Immune Monitoring, and Novel Technologies Autoimmunity;B cell;Biomarkers;Carcinogenesis;Immune monitoring;Solid tumors;Tumor microenvironment;Tumor stroma
23 Poster Presentation Validation of PD-L1 dynamic expression on extracellular vesicles as a predictor of response to immune-checkpoint inhibitors and survival in non-small cell lung cancer patients Diego de Miguel Perez, PhD, MSc; Feliciano Barrón, MD, MSc; Alessandro Russo, MD, PhD; Luis Lara-Mejía, MD; Muthukumar Gunasekaran, PhD; Andrés F. Cardona, MD, PhD; Christine B. Peterson, PhD; Rivka R. Colen, MD; Aung Naing, MD; Philip C. Mack, PhD; Fred R. Hirsch, MD, PhD; Vincenzo Adamo, MD, PhD; Oscar Arrieta, MD, PhD; Christian Rolfo, MD, PhD, MBA, Dr.hc. Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Extracellular vesicles/exosomes;Solid tumors;Tumor microenvironment
24 Poster Presentation Nivolumab Serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome. Domenico Mallardo, MD; Maria Grazia Vitale, MD; Diana Giannarelli, MD; Giusy Trillò; Assunta Esposito, PhD; Mariaelena Capone, MD; Maria Antonietta Isgrò; Gabriele Madonna, MS; grazia d'angelo; Lucia Festino; Vito Vanella; Claudia Trojaniello; Alessandro Manzoni; Andrew M. White, BSc; Michael Bailey; Ester Simeone, MD; Corrado Caracò; Piera Maiolino; Nicola Normanno; Sarah E. Warren, PhD; Ernesta Cavalcanti; Paolo A. Ascierto, MD Biomarkers, Immune Monitoring, and Novel Technologies Antibody;Antigen presenting cells;Biomarkers;Checkpoint blockade;Gene expression;Immune suppression;T cell
25 Poster Presentation Potential role of serum proteome in predicting immune-related adverse events from immunotherapy in non-small cell lung cancer Leeseul Kim, MD; Young Kwang Chae, MD, MPH, MBA; Dong-Uk Lee Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Immune toxicity
26 Poster Presentation Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials Heinrich Roder, DPhil; Laura Maguire, PhD; Senait Asmellash, PhD; Steven Rightmyer; Patrick Norman; Mark McCleland, PhD; Wei Zou, PhD; Minu Srivastava, PhD; Lelia Net, PhD; Thomas Campbell, PhD; David Shames, PhD; Robert Georgantas III, PhD; Joanna Roder, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Proteomics;Solid tumors
27 Poster Presentation Cytokine signature of PD-1, CXCL10, and TNF-alpha predicts response to nivolumab and ipilimumab Jesper G. Pedersen; Mateo Sokac; Nicolai J. Birkbak; Trine H. Øllegaard; Martin R. Jakobsen Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Cytokine
28 Poster Presentation Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology Joanna Roder, PhD; Thomas Campbell, PhD; Senait Asmellash, PhD; Steven Rightmyer; Patrick Norman; Robert Georgantas III, PhD; Mark McCleland, PhD; Wei Zou, PhD; Minu Srivastava, PhD; Lelia Net, PhD; Laura Maguire, PhD; Heinrich Roder, DPhil; David Shames, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Proteomics;Solid tumors
29 Poster Presentation Elevated Flt3L predicts long-term survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms Katharina Detjen; Raik Otto; Yvonne Giesecke; Lukas Geisler; Pamela Riemer; Henning Jann; Carsten Grötzinger; Christine Sers; Tom Luedde; Ulf Leser; Bertram Wiedenmann; Michael Sigal; Frank Tacke; Christoph Roderburg; Linda Hammerich, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Cytokine;Gene expression;Immune contexture;Solid tumors;Tumor microenvironment
30 Oral Presentation Blood-based Glycoprotein Signatures in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Receiving First-Line Immune Checkpoint Blockade Klaus Lindpaintner, MD, MPH; Michael Cheng; Jillian M. Prendergast, PhD; Karl Normington, PhD, MBA; Maurice Y. Wong; Gege Xu; Xini Cong; Rachel Rice; Marissa N. Lawrence; Kesi Michael; Daniel Serie Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Systems biology;Targeted therapy
31 Poster Presentation Serum LAG-3 is associated with improved patient prognosis in high grade serous ovarian cancer. Nicole E. James, PhD; Katrin Eurich; Erin Lips; Payton De La Cruz; Morgan Woodman; Jennifer Ribeiro Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Solid tumors
32 Poster Presentation Measuring soluble CD73 activity in high concentrations of human plasma to assess pharmacodynamics of CD73 inhibitors Rick Sorensen, BS; Marianna Zavodovskaya, M.S.; Ping Cheng Yi, M.S.; Michael Lee, B.A.; Audrey D. Goddard, Ph.D.; Matthew L. Peach, MS Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Immune suppression;Tumor microenvironment
33 Poster Presentation Development of a clinical ex vivo assay for the assessment of therapeutic CD28 costimulatory pathway engagement Chelsea J. Gudgeon, BS; Mark F. Maurer, BS; Gary D. Means, PhD, MS; Sherri Mudri, BS; Lori Blanchfield, PhD; Jing Yang, PhD; Stacey R. Dillon, PhD; Pamela M. Holland, PhD; Zelanna Goldberg, MD; Stanford Peng, MD Biomarkers, Immune Monitoring, and Novel Technologies Antigen presenting cells;Biomarkers;Costimulation;Immune monitoring;T cell
34 Poster Presentation Selective infiltration of Antibody-Dependent Cellular Cytoxicity (ADCC) mediating immune cells in response to treatment in a human tumor histo-culture platform Satish Sankaran, PhD; Nandini Basak, PhD; Sindhu Govindan, PhD; Prakash BV; Manjula BV; Ganesh MS; Amritha Prabha; Kowshik Jaganathan, PhD; Vasanth K, PhD; Gowri Shankar K, PhD; Manimaran A, PhD; Rajashekar M; Ritu Malhotra; Oliyarasi M; Rachita Rao Biomarkers, Immune Monitoring, and Novel Technologies Antibody;Chemokine;Immune monitoring;Monocyte/Macrophage;NK/NKT cell;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
35 Poster Presentation Chemokine-driven spatial organization of immune cell microaggregates marks oropharyngeal squamous cell carcinomas containing tumor-specific T cells Ziena Abdulrahman, MD; Saskia J. Santegoets; Gregor Sturm; Pornpimol Charoentong; Marieke E. Ijsselsteijn; Antonios Somarakis; Thomas Höllt; Francesca Finotello; Zlatko Trajanoski; Sylvia L. van Egmond; Dana AM. Mustafa; Marij J. Welters, PhD; Noel F. de Miranda, PhD; Sjoerd H. van der Burg, Prof.Dr. Biomarkers, Immune Monitoring, and Novel Technologies Antigen presenting cells;Biomarkers;Chemokine;Dendritic cell;Gene expression;MDSC;Solid tumors;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
36 Poster Presentation Digital Whole Slide Image (WSI) Scoring is Equivalent to Microscope Glass Slide Scoring for Evaluation of Programmed Death-Ligand 1 (PD-L1) Expression Across Multiple Tumor Indications Micki Adams, BS; Deanna Moquin, BS; Joshua Littrell, BA; Jay Milo, M.A.S; Stephanie Hund, B.S.; Angeliki Apostolaki, Ph.D. Biomarkers, Immune Monitoring, and Novel Technologies Antibody;Biomarkers;Checkpoint blockade;COVID and Immunotherapy;Solid tumors;Targeted therapy;Tumor evasion
37 Poster Presentation Quantitative Lung Airway Morphology (QuaLM) features on chest CT scans are associated with response and overall survival in lung cancer patients treated with checkpoint inhibitors Mehdi Alilou, PhD; Thomas Patton, BS; Pradnya Patil; Nathan Pennell; Kaustav Bera, MBBS; Amit Gupta; Pingfu Fu, PhD; Vamsidhar Velcheti; Anant Madabhushi, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Targeted therapy
38 Poster Presentation Spatial immune profiling of human glioblastoma tissue reveals the presence of aggregated lymphoid niches in the tumor microenvironment. Todd Bartkowiak, Ph.D.; Asa A. Brockman, B.S.; Sierra M. Barone, B.S.; Madeline J. Hayes, B.S.; Caroline E. Roe, MLI; Justine Sinnaeve, Ph.D.; Akshitkumar M. Mistry, M.D.; Nalin Leelatian, M.D.,Ph.D; Allison R. Greenplate, Ph.D.; Bret C. Mobley, M.D.; Lola B. Chambless, M.D.; Reid C. Thompson, M.D.; Kyle D. Weaver, M.D.; Rebecca A. Ihrie, Ph.D.; Jonathan M. Irish, Ph.D. Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Immune contexture;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
39 Poster Presentation A multi-modal analysis approach leveraging multiplexed spatial phenotyping and multi-omics analysis to better understand the prognostic value of tertiary lymphoid structures in NSCLC Julie Berthe, PhD; Sriram Sridhar; Felix Segerer; Marco Testori; Megha Saraiya; Lorenz Rognoni; Harald Hessel; Alma Andoni; Anatoliy Shumilov, PhD; Andreas Spitzmüller; Mari Heininen-Brown; Jorge Blando; Felicia Ng; Emma Jones; Sophie Willis; Michael Surace; Rieneke van de Ven; Tanja D. de Gruijl, PhD; Helen K. Angell, PhD, BSc Biomarkers, Immune Monitoring, and Novel Technologies B cell;Biomarkers;Dendritic cell;Gene expression;Immune contexture;Immunoscore;RNA;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
40 Poster Presentation Precise Spatial Multiplexing for Immune Profiling in Non-Small Cell Lung Cancer FFPE Samples with ChipCytometry Thomas Campbell, Ph.D.; Arne Christians, Ph.D; Adam Northcutt, Ph.D.; Crystal Winkeler, Ph.D.; Kevin Gamber, Ph.D. Biomarkers, Immune Monitoring, and Novel Technologies Immune monitoring;Tumor microenvironment;Tumor stroma
41 Poster Presentation Assessment of the spatial distribution of CD4+ T cells subpopulations in the tumor microenvironment by Brightplex®, a sequential chromogenic multiplex assay aurelie Collignon; Alex Trinh; Marion Olive; Clémence Jaume; Maïté Chamourin; Nour Sfeir; Dylan Anselmo; Raana Ramouz-Charpentier; Georgia Culey; Christophe Haond; Jerome Galon, PhD; Jacques Fieschi-Meric, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Immune contexture;Immune monitoring;Regulatory T cell (Treg cell);T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
42 Poster Presentation The role of tissue stiffness in predicting the immunotherapy response in hepatocellular carcinoma Betul Gok Yavuz, MD-PhD; Elshad Hasanov; Lianchun Xiao; Yehia I. Mohamed; Sunyoung S. Lee; Asif Rashid, MD, PhD; Ahmed O. Kaseb, MD; Aliya Qayyum, MD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade
43 Oral Presentation Intravital multiphoton imaging of infiltrating CD8 T cell and tumor cell metabolism during immunotherapy in a murine melanoma model Alexa R. Heaton, PhD; Anna Hoefges, MS; Peter R. Rehani, BS; Angelica F. Lopez; Nathaniel J. Burkard; Alexander L. Rakhmilevich, MD, PhD; Amy K. Erbe, PhD; Paul M. Sondel, MD, PhD; Melissa C. Skala, PhD Biomarkers, Immune Monitoring, and Novel Technologies Antibody;Checkpoint blockade;Metabolism;Radiotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
44 Poster Presentation Detection of memory B cells cross-reactive against polymorphic malaria antigens using a multiplex FluoroSpot assay David R. Spezzano; Peter Jahnmatz; Evan R. Johnson Biomarkers, Immune Monitoring, and Novel Technologies Antibody;Antigen presenting cells;B cell;Biomarkers;Cytokine;Immune monitoring;Immune tolerance;Inflammation;T cell;Vaccine
45 Poster Presentation AI-assisted whole-body assessment of immunotherapy response using [18F]F-AraG, a PET agent for activated T cells Jelena Levi, PhD; Timothy Perk, PhD; Lyna Huynh; Juliet Packiasamy, PhD; Serena Cheng, PhD; John B. Sunwoo, MD; A. Dimitrios Colevas, MD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs)
46 Poster Presentation Proximity between cytotoxic antigen-experienced T cells and tumor cells is associated with improved clinical outcomes in early-stage NSCLC Qianyun Luo; Marcelo V. Negrao, MD; Edwin R. Parra, MD, PhD; Neal Akhave, MD; Erin M. Bayley, MD; Kyle Mitchell, MD; Jianjun Zhang, MD, PhD; John V. Heymach, MD, PhD; Boris Sepesi, MD; Ignacio Wistuba, MD; Don L. Gibbons, MD, PhD; Alexandre Reuben, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Solid tumors;Tumor microenvironment
47 Poster Presentation Tertiary lymphoid structures (TLS) in desmoplastic melanomas (DM) differ from non-DM-associated TLS by their intratumoral location and enhanced immune activity Ileana S. Mauldin, PhD; Anne M. Stowman, MD; Alexandra W. Hickman, MD; Adela Mahmutovic; Alejandro A. Gru, MD; Kevin T. Lynch, MD; Samuel J. Young; Max O. Meneveau, MD; Nolan A. Wages, PhD; Victor H. Engelhard, PhD; Craig L. Slingluff Jr, MD Biomarkers, Immune Monitoring, and Novel Technologies B cell;T cell;Tumor microenvironment
48 Poster Presentation Immune Environment Correlates with NSCLC and CRC Patient Survival Dannah Miller, PhD; Dannah Miller; Huong Nguyen; Kate Hieber; Charles Caldwell, Jr., PhD; Roberto Gianani, MD, FCAP Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Immune monitoring;Immune suppression;Monocyte/Macrophage;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
49 Poster Presentation Highly multiplexed detection of critical immune checkpoints and immune cell subtypes in cancerous FFPE tissues using CODEX Olive Shang; Judi Gordon; Nadya Nikulina; Sejal Mistry; Jasmine Singh; Hailing Zong; Jessica Yuan; Trillium Blackmer; Darren Locke; Oliver Braubach; Julia Kennedy-Darling; Peter Miller Biomarkers, Immune Monitoring, and Novel Technologies B cell;Bioinformatics;Biomarkers;Dendritic cell;Immune contexture;Solid tumors;Systems biology;T cell
50 Poster Presentation In-situ visualization and measurement of tumor-infiltrating lymphocytes (TILs) on intact FFPE renal cell carcinoma (RCC) tissue using the spatial molecular imager (SMI) Evan W. Newell, PhD; Youngmi Kim, PhD; Heeju Ryu; Shamin Li, PhD; Michael Leon; Sean Kim; Mark Gregory; Patrick Danaher, PhD; Joseph M. Beechem, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Immune contexture;Immune monitoring;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
51 Poster Presentation A novel cross-site analysis of Vectra® Polaris™ multiplex fluorescence PD-1/PD-L1 immunohistochemistry on colorectal cancer with high and low microsatellite instability Sara Pollan, phD; Bethany Remeniuk, PhD; Arezoo Hanifi, PhD; Kristin Roman; Bei Hopkins; Natalie Monteiro; Harry Nunns, PhD; Erinn A. Parnell, PhD; Josette William, MD, PhD; Qingyan Au, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Regulatory T cell (Treg cell);Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
52 Poster Presentation Characterization of the tumor microenvironment in melanoma using Multiplexed Ion Beam Imaging (MIBI) Jason Ptacek, PhD; Matthew D. Vesely, MD, PhD; David L. Rimm, MD, PhD; Monirath Hav, MD; Murat Aksoy, PhD; Ailey Crow; Jessica Finn, MD Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Biomarkers;Immune monitoring;Monocyte/Macrophage;Proteomics;Systems biology;T cell;Tumor microenvironment
53 Poster Presentation Unique insights into PDAC development revealed by both InSituPlex® and Imaging Mass Cytometry Andrew Quong, PhD; Mark L. Rees; Kirsteen H. Maclean, Ph.D; Mael Manesse, PhD; Jordan Nieto; Amanda Esch; Devan Fleury; Keith Wharton, MD, PhD; Gourab Chatterjee Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Immune contexture;Immune monitoring;Proteomics;Solid tumors;T cell;Tumor microenvironment;Tumor stroma
54 Poster Presentation A strategy to quantitatively assess the accuracy and precision of multiplex immunofluorescence assays - application to Ultivue Insituplex® PD-L1, T-act and APC panels Sripad Ram, PhD; Eric L. Powell, MD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs)
55 Poster Presentation Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors Saulo B. Silva, Sr., MD; Carlos Wagner Wanderley, PhD; Jose Flavio G. Marin, PhD; Mariana P. De Macedo, PhD; Ellen CT. Nascimento, PhD; Fernanda F. Antonacio, MD; Fernando Q. Cunha, PhD; Gilberto de Castro Jr, MD, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Metabolism;Solid tumors
56 Poster Presentation Quantitative evaluation of the tissue micro-environment by high-resolution 17-plex immunofluorescence reveals distinct cell populations Kyla Teplitz; Daniel Campton, BS; Erin McCarty; Jeremy Cooper; Anne E. Hellebust, PhD; Donald Allen; Kimberly Collins; Kate Lillard, PhD; Eric P. Kaldjian, MD; Tad George, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Immune monitoring;Leukemia/Lymphoma;Monocyte/Macrophage;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor microenvironment
57 Poster Presentation Assessment of the spatial distribution of B cells subpopulations in the tumor microenvironment and tertiary lymphoid structures by Brightplex®, a sequential chromogenic multiplex assay Alex Trinh; Aurélie Collignon; Marion Olive; Clémence Jaume; Maïté Chamourin; Nour Sfeir; Dylan Anselmo; Raana Ramouz-Charpentier; Georgia Culey; Christophe Haond; Jerome Galon, PhD; Jacques Fieschi-Meric, PhD Biomarkers, Immune Monitoring, and Novel Technologies B cell;Biomarkers;Immune contexture;Immune monitoring;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
58 Poster Presentation Analytical validation of a novel immunohistochemistry assay to determine nuclear AHR expression in human bladder cancer Lei Wang, PhD; Marta Sanchez-Martin, PhD; Steve Tirrell, PhD; Nerymar Ortiz-Otero, PhD; Michelle Zhang, PhD Biomarkers, Immune Monitoring, and Novel Technologies Immune suppression;Tumor microenvironment
59 Poster Presentation Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial Arika S. Feils, BS; Amy K. Erbe, PhD; Jen Birstler; KyungMann Kim, PhD; Ute Hoch, PhD; Sue L. Currie, PhD; Tuan Nguyen, PhD; Danni Yu; Arlene O. Siefker-Radtke, MD; Nizar M. Tannir, MD, FACP; Matthew D. Hellmann, MD; Sara Tolaney; Adi Diab, MD; Paul M. Sondel, MD, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Gene expression;Genetic polymorphism;NK/NKT cell;Solid tumors
60 Poster Presentation Use of the Combined Positive Score (CPS) with the companion diagnostic PD-L1 IHC 22C3 pharmDx provides precise evaluation of PD-L1 expression across multiple tumor indications and cutoffs Francisco J. Ponce, BS; Stephanie Hund, B.S.; Lindsay Peltz, M.S.; Chris La Placa, M.S.; Monika Vilardo, B.S.; Brittany Watts, B.S.; Siena Tabuena-Frolli, B.A.; Grant Toland, B.S.; Alex Posch, B.S.; Jay Milo, M.A.S; Karina Kulangara, Ph.D.; Angeliki Apostolaki, Ph.D. Biomarkers, Immune Monitoring, and Novel Technologies Antibody;Biomarkers;Immune monitoring;Inflammation;Monocyte/Macrophage;Solid tumors;Tumor evasion
61 Poster Presentation Biomarkers of favorable prognosis guides the identification of tumor reactive CD4+ and CD8+ TILs in Endometrial Cancer Jara Palomero, PhD; Carla Panisello; August Vidal, MD; Jordi Ponce, MD, PhD; Ana Vivancos, PhD; Josep Maria Piulats, MD, PhD; Xavier Matias-Guiu, MD, PhD; Alena Gros, PhD Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy;Biomarkers;Solid tumors;Tumor infiltrating lymphocytes (TILs)
62 Poster Presentation Applying machine vision to empower preclinical development of cell engager and adoptive cell therapeutics in patient-derived organoid models of solid tumors. Sonal Khare, PhD; Chi-Sing Ho; Madhavi Kannan, MS; Brian M. Larsen, PhD; Brandon L. Mapes, MS; Jenna Shaxted; Jagadish Venkataraman, PhD; Ameen A. Salahudeen, MD PhD Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy;Bispecifics;CAR T cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
64 Poster Presentation A cloning and expression system of the neoantigen-specific TCRs from tumor-infiltrating lymphocytes by single-cell sequencing of paired TCRα and TCRβ chains Yukari Kobayashi, BS; Koji Nagaoka, PhD; Kaori Kubo; Toshikazu Nishie; Sachiko Okamoto, PhD; Tatsuji Enoki; Junichi Mineno, PhD; Yasuyoshi Sato, MD, PhD; Shunji Takahashi, MD, PhD; Jun Nakajima, MD, PhD; Kazuhiro Kakimi, MD, PhD Biomarkers, Immune Monitoring, and Novel Technologies Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
65 Poster Presentation Identification of frequently presented non-mutated tumor-specific immunogens for the development of both off-the-shelf and personalized vaccines without need for tumor biopsy Orsolya Lorincz, PhD; Levente Molnar, Msc; Zsolt Csiszovszki, PhD; Eszter Somogyi, PhD; Jozsef Toth, MSc; Katalin Pantya, MSc; Peter Pales, MSc; Eniko R. Toke, PhD Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;T cell;Tumor antigens;Vaccine
66 Oral Presentation Prognostic and predictive value of pre-treatment T-Cell receptors (TCR) repertoire in non-small cell lung cancer (NSCLC) patients treated with single agent immunotherapy. Afaf Abed, MBBS, FRACP; Elin S. Gray; Michael Millward, MD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade
67 Poster Presentation Cancer aneuploidy is associated with a distinct tumor immune microenvironment and impacts outcomes to immune checkpoint inhibition in nonsquamous non-small cell lung cancer. Joao Victor M. Alessi, MD; Biagio Ricciuti, MD; Yvonne Lin-Liu; Hersh Gupta; Xinan Wang; Giuseppe Lamberti, MD; Gonzalo Recondo, MD; Victor R. Vaz; Adriana Barrichello; Mizuki Nishino; Andrew D. Cherniack, PhD; James Lindsay; Bijaya Sharma; Kathleen L. Pfaff; Kristen D. Felt; Scott J. Rodig, MD, PhD; Mark Awad, MD, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade
68 Poster Presentation Rapid detection of somatic variants in human leukocyte antigen class 1 genes from solid tumor samples. Ramit Bharanikumar, MS; Aly A. Khan, PhD; Karl Beutner; Jason Perera, PhD Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Immune monitoring;Immune suppression;Immune tolerance;Immune toxicity
69 Poster Presentation Immunophenotyping of TCR and BCR clonotypes Alex Chenchik, PhD; Michael Makhanov; Russell Darst; Tianbing Liu; Lester Kobzik Biomarkers, Immune Monitoring, and Novel Technologies B cell;Bioinformatics;Biomarkers;Gene expression;Immune monitoring;NK/NKT cell;Regulatory T cell (Treg cell);RNA;T cell;T cell lineages
70 Poster Presentation Novel Immunotherapeutic Targets in Cancer of Unknown Primary (CUP) Mary Nesline, M.S.; Paul DePietro, PhD; Yong Hee Lee, M.S.; Zachery Bliss; R.J. J. Seager, Jr., Ph.D.; Erik Van Roey; Shuang Gao; Vincent Giamo; Blake Burgher; Sean T. Glenn, PhD; Shengle Zhang, MD; Sarabjot Pabla; Roger D. Klein, MD, JD, FACP; Jeffrey Conroy, BS Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Gene expression;Solid tumors
71 Poster Presentation Tumors with Higher Heterogeneity Were Associated with Superior Survival Outcome Amongst Stage I Lung Cancer Patients With Low Tumor Mutational Burden (TMB) Stanislav Fridland, BS; Young Kwang Chae, MD, MPH, MBA Biomarkers, Immune Monitoring, and Novel Technologies B cell;Bioinformatics;Biomarkers;Gene expression;MDSC;Regulatory T cell (Treg cell);RNA;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
72 Poster Presentation Spatial whole transcriptome profiling of the tumor microenvironment in prostate carcinomas. Naishitha Anaparthy, PhD; Valeria Giangarra; Sarah E. Taylor; Mesruh Turkekul; Stephen R. Williams, PhD; Paulius Mielinis; Caroline Gallant Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Gene expression;RNA;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
73 Poster Presentation Characterization of tumor-infiltrating T-cell repertoire in human cancers Taylor Harding, Ph.D.; Qidi Yang; Brittany Mineo; Jenna Malinauskas; Jason Perera, PhD; Karl Beutner; Denise Lau, PhD; Aly A. Khan, PhD Biomarkers, Immune Monitoring, and Novel Technologies Immune monitoring;RNA;T cell;Tumor microenvironment
74 Poster Presentation Tumor Microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the response of MSS mCRC patients treated vactosertib in combination with pembrolizumab Tae Won Kim, MD; Keun-Wook Lee, MD; Joong Bae Ahn, MD; Young Suk Park, MD; Chan-Young Ock, MD, PhD; Hyejoo Park, PhD; Jiyeon Ryu, PhD; Bitna Oh, MD; Bo-Kyoung Kim, MD; Sunjin Hwang, MD; Ki Baik Hahm, MD; Seong-Jin Kim, PhD Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Biomarkers;Checkpoint blockade;Clinical study;Gene expression;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
75 Poster Presentation Comprehensive profiling of the tumor-immune microenvironment using an augmented transcriptome Eric Levy, PhD; Pamela Milani, PhD; Fabio Navarro; Gabor Bartha, PhD; Charles W. Abbott, PhD; Jose Jacob, MS; Rena McClory, PhD; Robin Li, MS; John S. West, MBA; John Lyle, PhD; Sean M. Boyle, PhD, MS; Richard Chen, MD Biomarkers, Immune Monitoring, and Novel Technologies B cell;Bioinformatics;Biomarkers;Gene expression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
76 Oral Presentation Spatial mapping of T cell receptors and transcriptomes in renal cell carcinoma following immune checkpoint inhibitor therapy Sophia Liu; Bryan Iorgulescu, MD; Shuqiang Li, PhD; Julia Morriss; Mehdi Borji; Evan Murray; David A. Braun; Kenneth J. Livak; Catherine J. Wu, MD; Fei Chen Biomarkers, Immune Monitoring, and Novel Technologies Gene expression;RNA;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
77 Poster Presentation Prevalence of Secondary Immunotherapeutic Targets in the Absence of Established Immune Biomarkers in Solid Tumors Paul DePietro, PhD; Mary Nesline, M.S.; Yong Hee Lee, M.S.; R. J. Seager; Erik Van Roey; Shuang Gao; Vincent Giamo; Blake Burgher; Sean T. Glenn, PhD; Shengle Zhang, MD; Roger D. Klein, MD, JD, FACP; Sarabjot Pabla; Jeffrey Conroy, BS Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;T cell;Tumor antigens
78 Poster Presentation Novel RNA-seq Platform Improve Patient Outcome in Clinical Oncology and enable implementation of AI in the clinic Vy Nguyen, B.S; Gitte Pedersen, MSc; Morten Pedersen Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Biomarkers;Chemotherapy;Gene expression;RNA;Solid tumors
79 Poster Presentation Extensively validated HLA LOH algorithm demonstrates an association between HLA LOH and genomic instability Rachel M. Pyke, PhD; Steven Dea, MS; Dattatreya Mellacheruvu, PhD; Charles W. Abbott, PhD; Simo V. Zhang, PhD; Lee D. McDaniel, Jr., MD, MSE; Eric Levy, PhD; Gabor Bartha, PhD; John S. West, MBA; Michael P. Snyder, PhD; Richard Chen, MD; Sean M. Boyle, PhD, MS Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Biomarkers;Checkpoint blockade;Genetic polymorphism;Neoantigens;Tumor antigens;Tumor evasion;Vaccine
80 Poster Presentation Cancer testis antigen burden: A novel predictive biomarker for immunotherapy in solid tumors Sarabjot Pabla; R. J. Seager; Yong Hee Lee, M.S.; Erik Van Roey; Shuang Gao; Vincent Giamo; Blake Burgher; Paul DePietro, PhD; Mary Nesline, M.S.; Sean T. Glenn, PhD; Shengle Zhang, MD; Jeffrey Conroy, BS Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;Tumor antigens
82 Poster Presentation Single-cell RNA sequencing and CITE-Seq analysis of bladder cancer patient urine with matched tumor and peripheral blood suggests urine as a window into the tumor immune microenvironment Michelle Tran, MD PhD Candidate; Adam M. Farkas, PhD; Kristin G. Beaumont; Timothy O'Donnell, PhD; Reza Mehrazin, MD; Amir Horowitz, PhD; Peter Wiklund, MD, PhD; Matthew D. Galsky, MD; John P. Sfakianos, MD; Nina Bhardwaj, MD, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Gene expression;Immune monitoring;Immune suppression;Monocyte/Macrophage;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
83 Poster Presentation Spatially Resolved Transcriptomic and Proteomic Investigation of Breast Cancer and its Immune Microenvironment Jennifer Chew, BS; Cedric R. Uytingco, PhD; Rapolas Spalinskas; Yifeng Yin, PhD; Joe Shuga; Benton Veire; Naishitha Anaparthy; Ryo Hatori; Anna-Maria Katsor; Layla Katiraee; Alexander Hermes; Jun Ding Chiang; Patrick Roelli; Stephen R. Williams, PhD; William Nitsch; Neil Weisenfeld, PhD; Dan Walkser; Jason Koth; Subham Basu, PhD; Will Howat; Karthik Ganapathy; Marlon Stoeckius Biomarkers, Immune Monitoring, and Novel Technologies Gene expression;Proteomics;Tumor microenvironment
84 Poster Presentation Comparative analysis of ImmunoID NeXT™ and ACE ImmunoID™ next generation sequencing platforms for investigating tumor-immune interactions to enable precision oncology driven biomarker discovery Danyi Wang, PhD; Juergen Scheuenpflug, PhD; Zheng Feng Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;Tumor microenvironment
85 Poster Presentation Detection of human angiotensin-converting enzyme 2 receptor (hACE2R) on human cancer cell lines. Tarsem L. Moudgil, MS; Bernard A. Fox, PhD; Hong-Ming Hu, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers
86 Poster Presentation Extensive FAP expression analysis in 23 tumor indications and potential application in defining the patient population in FAP-targeting cancer immunotherapies Sebastian Dziadek, PhD; Anton Kraxner; Wei-Yi Cheng; Mike Flores, PhD; Tai-Hsien tai-hsien.ou_yang@roche.com, PhD; Noah Theiss, PhD; Tsu-Shuen Tsao, PhD; Emilia Andersson; Suzana Vega Harring; Gabriele Gabriele Hoelzlwimmer, Dr.; Ann-Marie Broeske; Maurizio Ceppi; Jehad Charo; Sebastian Dziadek Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Clinical trial;Immune contexture;Solid tumors;Tumor antigens;Tumor evasion;Tumor microenvironment;Tumor stroma
87 Poster Presentation Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known Ahmad A. Tarhini, MD, PhD, MS; Aik Choon Tan, PhD; Issam El Naqa, PhD; Sandra Lee, ScD; F. Stephen Hodi, Jr., MD; Lisa H. Butterfield, PhD; William A. LaFramboise, PhD; Walter J. Storkus, PhD; Jose R. Conejo-Garcia, MD, PhD; Patrick Hwu; Howard Streicher, MD; Vernon K. Sondak, MD; John M. Kirkwood, MD, MD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Gene expression;Immune monitoring;Tumor microenvironment
88 Poster Presentation Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males Mariam Saad, MD; Aik Choon Tan, PhD; Issam El Naqa, PhD; Sandra Lee, ScD; F. Stephen Hodi, Jr., MD; Lisa H. Butterfield, PhD; William A. LaFramboise, PhD; Walter J. Storkus, PhD; Jose R. Conejo-Garcia, MD, PhD; Patrick Hwu; Howard Streicher, MD; Vernon K. Sondak, MD; John M. Kirkwood, MD, MD; Ahmad A. Tarhini, MD, PhD, MS Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Immune monitoring;Tumor microenvironment
89 Poster Presentation The immune marker LAG-3 increases the predictive value of CD38+ immune cells for survival outcome in immunotherapy-treated hepatocellular carcinoma Chun Chau Lawrence Cheung, MMedSc; Yong Hock Justin Seah; Juntao Fang; Nicole HC. Orpilla; Justina Nadia Li Wen Lee; Han Chong Toh, MD; Su Pin Choo; Kiat Hon T. Lim; Wai Meng David Tai; Joe P. Yeong, MD, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Checkpoint blockade;Immune contexture;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
90 Poster Presentation Unbiased proteomic profiling leads to the discovery of a novel non-invasive blood-based protein panel with significant positive predictive value in pancreatic and colorectal cancers Kristina Beeler, Dr.; Roland Bruderer, PhD; Marco Tognetti, PhD; Kamil Sklodowski, PhD; Sebastian Mueller, PhD; Dominique Kamber; Lukas Reiter, PhD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Proteomics;Solid tumors
91 Poster Presentation Impact of ultra-fast 'FLASH' radiotherapy on single cell immunogenomics in diffuse intrinsic pontine glioma (DIPG) Oscar Padilla, MD; Hanna Minns, BS; Hong-Jian Wei, PhD; Andrea Webster-Carrion, MD; Masih Tazhibi, BA; Nicholas McQuillan, BS; Xu Zhang, PhD; Zhiguo Zhang, PhD; Raul Rabadan, PhD; Peter Canoll, MD PhD; Luca Szalontay, MD; Jovana Pavisic, MD; Guy Garty, PhD; Stergios Zacharoulis, MD; Claire I. Vanpouille-Box, PhD; Vilas Menon, PhD; Marta Olah, PhD; Cheng-Chia Wu, MD PhD; Robyn D. Gartrell, MD Biomarkers, Immune Monitoring, and Novel Technologies Gene expression;Pediatric tumors;Radiotherapy;Tumor microenvironment
92 Poster Presentation Single cell and spatial multiplex profiling of immune cell markers in FFPE tumor tissues using the novel RNAscope™ HiPlex v2 in situ hybridization assay Sayantani Basak; Anushka Dikshit; Ming Yu; HaYeun Ji; Ching-Wei Chang; Bingqing Zhang Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Gene expression;Immune monitoring;Immune suppression;RNA;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
93 Poster Presentation Computational biology and tissue-based approaches to inform indication selection for a novel AHR inhibitor Marta Sanchez-Martin, PHD; Lei Wang, PhD; Jeffrey Ecsedy; KAREN MCGOVERN, PhD; Michelle Zhang, PhD; Marta Sanchez-Martin, PhD Biomarkers, Immune Monitoring, and Novel Technologies Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;Systems biology;Targeted therapy
94 Poster Presentation ​Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC) Brie M. Chun, MD; Joanna Pucilowska, PhD; Shu Ching Chang, PhD; Isaac K. Kim, MD; Benjamin Nikitin; Yoshinobu Koguchi, MD, PhD; William L. Redmond, Ph.D.; Brady M. Bernard, PhD; Venkatesh Rajamanickam; Nathan W. Polaske; Paul Fields, PhD; Valerie K. Conrad, BS; Mark Schmidt; Walter J. Urba, MD, PhD; Alison K. Conlin, MD; Heather McArthur, MD; David B. Page, MD Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Clinical trial;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
95 Poster Presentation MAGE-A1 protein expression pattern in > 5,000 tumor and healthy tissue samples: Validation of MAGE-A1 as an ideal target for TCR-based cell therapy Jennifer D. Oduro, PhD; Ronald Simon, Prof. PhD; Natalia Gorbokon; Christoph Fraune, PD MD; Julia Bluhm, PhD; Vivian Scheuplein, PhD; Elisa Kieback, PhD; Matthias Obenaus, MD; Thomas Blankenstein, PhD; Eugen Leo, MD PhD MBA Biomarkers, Immune Monitoring, and Novel Technologies Adoptive immunotherapy;Biomarkers;Solid tumors;T cell;Targeted therapy;Tumor antigens
96 Poster Presentation The Impact of Radiographic Tumor Thickness on the Complexity of the Tumor Immune Microenvironment in Malignant Pleural Mesothelioma Katarzyna Tomczak, PhD; Jacqueline Liszeth Oliva, PhD; Nicolas Zhou, DO, MSc; Carlos Ramos; Nathaniel Deboeve, MD; Hope Feldman, MD; Percy Lee, MD; Chad D. Strange, MD; Annikka Weissferdt, MD; David C. Rice, MB, BCh; Reza J. Mehran, MD; Jianjun Zhang, MD, PhD; Anne Tsao, MD; Boris Sepesi, MD; Cara Haymaker, PhD Biomarkers, Immune Monitoring, and Novel Technologies Gene expression;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment

Late-Breaking

945 Poster Presentation Characterization of the immune landscape of malignant pleural effusion composition from patients with metastatic breast carcinoma: A Pilot study Caddie Dy Laberiano, MD; Edwin R. Parra, MD, PhD; Qiong Gan; Heladio Ibarguen; Shanyu RP. Zang; Esther Yoon; Biomarkers, Immune Monitoring, and Novel Technologies Biomarkers;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment